How big is the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market?

The Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size is expected to reach USD 3.94 billion in 2024 and grow at a CAGR of 5.90% to reach USD 5.25 billion by 2029. Read More

What is the current Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size?

In 2024, the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size is expected to reach USD 3.94 billion. Read More

Who are the key players in Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market?

Novo Nordisk, AstraZeneca, Eli lilly and Company, Sanofi and Pfizer are the major companies operating in the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market. Read More

What years does this Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market cover, and what was the market size in 2023?

In 2023, the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size was estimated at USD 3.72 billion. The report covers the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Glucagon-Like Peptide-1 (GLP-1) Agonists Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Europe GLP-1 Agonist Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers GLP-1 Agonists Brands & Drug List in Europe and the market is segmented into drugs (Dulaglutide, Exenatide, Liraglutide, Lixisenatide, and Semaglutide), brands (Byetta, Bydureon, Victoza, Trulicity, Lyxumia, and Ozempic) and Geography (Germany, Spain, Italy, France, United Kingdom, Russia, and Rest of Europe). The market provides the value (in USD million) for the above-mentioned segments.